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Preterm birth remains a major health issue worldwide. Since the 1990s, women at risk for preterm birth received a single course
of exogenous antenatal corticosteroids (ACSs) to facilitate fetal lung maturity. More recently, repeated or multiple courses of ACS
have been supported to provide continued fetal maturity support for women with continued risk of preterm birth. However,
exogenous ACS reduces birth weight which, in turn, is associated with adverse adult outcomes such as coronary heart disease,
stroke, hypertension, and type 2 diabetes. The long-term eﬀects of ACS exposure on HPA axis activity and neurological function
are well documented in animal studies, and it appears that ACS, regardless of dose exposure, is capable of aﬀecting fetal HPA
axis development causing permanent changes in the HPA axis that persists through life and is manifested by chronic illness and
behavioral changes. The challenge in human studies is to demonstrate whether an intervention such as ACS administration in
pregnancy contributes to developmental programming and how this is manifested in later life.
1.Introduction
The“developmentaloriginsofhealthanddisease”(DOHaD)
refers to a concept where exposure to environmental factors
such as maternal nutrition, body composition, and stress
hormone levels sends signals to a developing fetus that
potentially inﬂuences the metabolic phenotype of the oﬀ-
spring and its risk of chronic diseases later in life [1–5]. This
concept was originally developed to explain observations
between the high rates of death due to coronary heart disease
in areas of England and Wales with high neonatal mortality
andproposedthatintrauterinedeprivationwasanimportant
mediator [6]. Further studies found an inverse relationship
between birthweight and coronary heart disease [7]. The
association of low birth weight and increased incidence of
chronic illnesses of adulthood, such as heart disease, hyper-
tension, type 2 diabetes, has been documented in numerous
studies [8–12]. Low birth weight has been proposed as an
indicator of an environmental adversity during fetal devel-
opment and may suggest fetal processes or programming are
in place. Two mechanistic hypotheses have been proposed to
explain how fetal programming may arise: fetal malnutrition
and fetal overexposure to glucocorticoids both of which may
have eﬀects either directly or indirectly upon the developing
fetus. Exposure to excess glucocorticoids in utero acts to
program the fetal hypothalamic-pituitary-adrenal (HPA)
axis, permanently altering basal and stress-induced HPA axis
activity and regulation in the oﬀspring throughout life. Fetal
exposure to excess glucocorticoids can occur via a number of
mechanisms such as maternal stress during pregnancy and
maternal treatment with synthetic glucocorticoids (sGC),
more commonly known as antenatal corticosteroids (ACS).
This paper will focus on ACS and its eﬀect on the
developing HPA axis and building the case for the use of ACS
as a risk factor for the development of chronic disease in the
oﬀspring.
2. Development andFunction of the
Hypothalamic-Pituitary-Adrenal(HPA)Axis
Activation of the HPA axis after exposure to a stressor is
part of a normal adaptive response allowing the organism
to respond to changes in its environment [13]. Stress results2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
in activation of central neurocircuitry, which in turn signals
the hypothalamus to produce and secrete corticotrophin-
releasing hormone (CRH) and vasopressin (AVP). CRH and
AVP lead to the release of adrenocorticotrophic hormone
(ACTH) from the anterior pituitary which stimulates the
production and secretion of glucocorticoids (GC), prin-
cipally cortisol in humans. Cortisol binds the glucocorti-
coid receptors (GR) in multiple target tissues to maintain
homeostasis following stress. Cortisol also binds to GR
and mineralocorticoid receptors (MR) in the limbic regions
(including hippocampus and prefrontal cortex) to modify
behaviours and learning and memory. In addition, cortisol
acts to feedback and decrease HPA function in a classic
endocrine feedback loop. Tightly regulated feedback control
of cortisol is critical as prolonged tissue exposure to GC leads
to metabolic and behavioural disorders [14]. The timing of
maturation of the HPA axis relative to birth is highly species-
speciﬁc and is linked to landmarks of brain development.
In humans, like animals that give birth to mature young
(primates, sheep, and guinea pigs), maximal brain growth
and a large proportion of neuroendocrine maturation takes
place in utero [15, 16].
3. Role of 11β-HSD-2
Low levels of GC are critical for normal fetal development;
however, fetal exposure to elevated glucocorticoids can
inhibit growth and adversely impact brain development.
Under normal conditions, access of maternal cortisol to
the fetus is low due to the placental expression of the
enzyme, 11β-hydroxysteroid dehydrogenase-2 (11β-HSD-2)
[17]. Placental 11β-HSD-2 transforms cortisol into its much
less active 11-keto form, cortisone. This protective placental
enzymatic barrier is very eﬃcient, such that only 10–20% of
maternal cortisol crosses the placenta and reaches the fetus.
This 10–20% passage of active maternal GC to the fetus
reﬂects an anatomical bypass of the enzyme, presumably
adding to the provision of GC for normal key developmental
processes in the fetuses such as maturation of the lung and
other fetal organs [18].
Lowlevelsofplacental11β-HSD-2activityhavebeencor-
r e l a t e dw i t hl o wb i r t hw e i g h ti nh u m a n sa n dr o d e n tm o d e l s
[19–22]. Reduced levels of 11β-HSD-2 may contribute to
greater signaling within the placenta itself which may impact
fetal development by altering placental function. Rodent
studies have demonstrated that variations in placental 11β-
HSD-2 levels have correlated with altered expression in
glucose and amino acid transporter molecules as well as
growth factors in the placenta [23].
It is clear that placental 11β-HSD-2 plays a key role
in mediating the ﬂow of environmental signals to the
fetus. Animal studies have demonstrated that prenatal stress
c a nl e a dt oar e d u c t i o ni np l a c e n t a l1 1 β-HSD-2 activity
suggesting then that the fetus and placenta are exposed to
extra excessive amounts of GC [24]. In addition, dietary
protein restriction selectively reduces 11β-HSD-2 activity
suggesting a common mechanism by which malnutrition
a n de x c e s sG Cc a np r o g r a m m ea d u l tb i o l o g y[ 25, 26].
UnlikeendogenousGC,thesyntheticGCsutilizedasACS
(dexamethasone and betamethasone) are poor substrates for
11β-HSD-2 and readily passes the placenta barrier. This lack
of restriction allows ACS to exert its eﬀect in the same
manner as excessive endogenous GC.
4.Other Stress-Related
ProgrammingMediators
While it is clearly evident the role GC has on inﬂuencing
developmentundernormalandstress-relatedcircumstances,
other substances are released by the mother and fetus in
response to stress. Catecholamines, in particular adrenaline
and noradrenaline, are of importance since they are both
released by stress and may inﬂuence placental function and
also transport across the placenta to the fetus [27]. However,
more exploration in this area is required to determine how
these catecholamines function in normal and abnormal
situation and what contribution they may play in enhancing
disease risk.
5. Use of AntenatalCorticosteroids (ACSs)in
the Management of Women at
Risk for PretermBirth
Preterm delivery aﬀects over 7–12% of births in North
America alone and is responsible for up to 75% of neonatal
deaths [28, 29]. Despite advances in medical technology, the
prevalence of preterm birth worldwide is increasing [29].
Respiratory distress syndrome, as a consequence of
immature lung development, is a signiﬁcant risk of preterm
birth and the major cause of early neonatal mortality and
morbidity [30]. Infants born very preterm (less than 32
weeks of gestation) often require respiratory support, in
the form of positive pressure ventilation and prolonged
oxygen support. A substantial proportion have intraven-
tricular haemorrhages and associated “white matter brain
injury”(grade3or4intraventricularhaemorrhages,periven-
tricular leukomalacia), bronchopulmonary dysplasia, and
severe retinopathy of prematurity, all of which contribute
signiﬁcantly independently and combined to an adverse
neurodevelopmental outcome in later life [31, 32]. Infants
born preterm who survive have an increased risk of hos-
pitalizations [33]. The personal and emotional costs for
aﬀected individuals and their families are high, as are
the immediate and long-term monetary costs of these
morbidities for parents and society [33]. Thus, preterm birth
and preterm infants continue to remain a signiﬁcant health
issue worldwide.
The immature fetal lung is the target organ when women
at risk of preterm birth are given ACS. Stimulation of
the pulmonary surfactant system has been regarded as the
most important eﬀect of ACS. In addition, ACS can alter
lung ﬂuid absorption and alveolar development by inducing
genes associated with the synthesis of surfactant proteins,
fatty acid syntheses, the epithelial sodium channel, and the
membrane protein sodium/potassium ATPase [34, 35]. The
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maturation of the fetal lung and reduces the severity of
respiratorydistresssyndrome(RDS)intheﬁrstfewdaysafter
a preterm birth. This, in turn, contributes to a reduction
in mortality and other neonatal morbidities associated with
preterm birth. In 1972, Liggins and Howie published the
results of the ﬁrst RCT evaluating the eﬀects of a single
course of ACS [36]. Among those women who had been
in spontaneous preterm labour, ACS reduced the risk of
respiratory distress syndrome (RDS) (9.0% versus 25.8%,
P = 0.003) and early neonatal mortality (3.2% versus 15.0%,
P = 0.01). Over the subsequent 20 years, 12 additional RCT,
involving over 3000 infants, showed a beneﬁt of a single
course of ACS with no adverse eﬀects [37].
Since the early 1990s, the recommendation has been
that women, between 24 and 34 weeks of gestation and
at high risk of preterm birth, receive a single course of
ACS (2 doses of ACS 12 hours apart) [38, 39]. However,
approximately 50% of women given a ﬁrst course of ACS
remain undelivered 7–14 days later, and, for these women,
the question had arisen as to whether repeated courses of
ACS should be given [40]. There has been no consensus
on repeated courses of ACS in the management of women
at risk for preterm birth [41]. In the past decade, 10 trials
have been conducted to evaluate the risks and beneﬁts of
repeated courses of ACS to women at risk of preterm birth.
The most recent review in the Cochrane Database of these
trials involving over 4730 women and 5650 infants concludes
that repeat courses of ACS does reduce the risk of RDS (risk
ratio (RR) 0.83, 95% conﬁdence interval (CI) 0.75–0.91),
and serious infant outcomes (RR 0.84, 95% CI 0.75–0.94)
compared to no repeat ACS treatment [42]. However, these
beneﬁtswere associated with a signiﬁcant reduction in size at
birth. Because of this reduction in size at birth, concern over
the long-term eﬀects in the oﬀspring from repeated courses
of ACS has been raised, and more research on the long-term
eﬀects has been recommended [43].
6. Long-Term ClinicalSigniﬁcance of
ACSExposureinthe Offspring
Dalziel et al. reported on the cohort in the initial trial
by Liggins and did not identify overt neurological and
physiologicaleﬀectsofasinglecourseofACSinlategestation
but did identify early markers of insulin resistance [44,
45]. Retrospective studies evaluating the eﬀect of repeated
courses on neonates and children have been somewhat
conﬂicting; while they suggest beneﬁt in terms of lung
function in the neonatal period, there appears to be an
increased risk of other outcomes, namely, long-term eﬀects
on behavior [46–49]. The 2-year followup of the recent RCT
evaluating the use of repeated courses of ACS has reported
no signiﬁcant diﬀerences in the rate of deaths or major
neurodevelopmental diﬃculties at 2 years of age [42, 50–54].
However, caution must be exercised because measurements
at 2 years of age have limited predictive abilities and are only
moderately correlated with developmental outcomes at later
ages [55]. In addition, these outcome studies did not address
the question of potential programming eﬀect from ACS
and impact on chronic illness development. Several ongoing
studies are currently taking place to evaluate the children
closer to school age which include the Canadian Institutes
of Health Research (CIHR)- funded Multiple Antenatal
Corticosteroids Study 5-year followup (MACS-5) and the 6-
year evaluation of the ACTORDS participants [56]. MACS-5
is speciﬁcally designed to evaluate the eﬀect of ACS on the
developing brain, speciﬁcally the hippocampus, by assessing
m e m o r y ,a t t e n t i o n ,a n db e h a v i o u ra sw e l la sn e u r o c o g n i t i v e
abilities;theACTORDSstudyhasfocusedonneurocognition
in addition to other developmental abilities as well as early
biomarkers for chronic illness [56].
7. PotentialEffects of ACSduringPregnancy
Much of what is known about the eﬀect of ACS on various
structures is from animal studies.
7.1. Brain Development. Endogenous GC is important for
normal development of the central nervous system; circulat-
ing levels of GC are maintained at very low levels throughout
themajorityofgestation[57,58]. However, levels will change
to meet the needs of the developing brain during “critical
windows.” Studies have shown that 11β-HSD-2 in the fetal
human brain is silenced between 19 and 26 weeks which
would lead to localized increases in GC signaling [59, 60].
GC is necessary for neuronal maturation, remodeling of
axons and dendrite and cell survival [61, 62]. However,
sustained elevation or depletion of GC during these “critical
windows” of fetal development can modify brain structure
with signiﬁcant consequences to future function [63, 64].
Prenatal GC administration has been shown to retard brain
weight at birth in sheep [65], as well as delay maturation of
neurons, myelination, glia, and vasculature [60]. It has been
shown to have widespread eﬀect on neuronal structure and
synapse formation and altered hippocampal structure and
volume which can aﬀect memory and attention [60, 65–68].
The hippocampus highly expresses GR and MR and, as
such, is vulnerable to high sustained levels of GC. Rodent
models show that prenatal stress decreases synaptic spine
density and neurogenesis which correlates with deﬁcits in
cognition and learning. Similar eﬀects are seen in pri-
mates (baboons and rhesus monkeys) where exposure to
dexamethasone or betamethasone leads to reduced levels
of neuritogenesis and neuronal plasticity and pronounced
degeneration of areas within the hippocampus. These eﬀects
were dose associated suggesting multiple exposures induced
more severe damage that a single injection [68–72].
7.2. HPA Axis. A number of animal models have shown
that maternal administration of sGC during pregnancy has
profoundacuteandlong-termeﬀectsonthedevelopingHPA
axis. The fetal brain contains high levels of GR over the
2nd and 3rd trimesters, with highest levels in the limbic
system (which includes prefrontal cortex, hippocampus and
amygdala),thehypothalamusparaventricularnucleus(PVN;
source of CRH and AVP), and the anterior pituitary (site
of ACTH production) [73]. Exposure of these structures4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
to high levels of GC can lead to permanent programming
of the function of these structures. This “programming”
takes place via modiﬁcation of both the GR and MR levels
in the hippocampus, hypothalamus, and pituitary gland.
Prenatal exposure to sGC leads to permanent changes in the
expression of GRs and MRs in these structures resulting in
altered negative feedback sensitivity and altered set points




including learning and attention [74].
The eﬀects of sGC are also noted to be sex dependent
[75, 76]. Administration of a single course of sGC in a guinea
pig model in a dose and regimen comparable to that used
in humans demonstrated signiﬁcantly increased levels of MR
andGRinthebrainsoffemale-exposedguineapigs.Multiple
course exposure to sGC in the same model resulted in dose-
dependent reductions in hippocampal NMDA-receptors in
the hippocampus and modiﬁcation of hippocampal long-
term potentiation (LTP; the biological substrate of learning
and memory), in female but not male oﬀspring [77, 78].
Limited studies have been undertaken to establish the
long-term eﬀects of fetal exposure to sGC on the HPA axis
function in nonhuman primates. Uno et al. [79]a n dd e
Vries et al. [80] were both able to demonstrate that repeated
e x p o s u r et os G Ci nr h e s u sm o n k e y sa n dV e r v e tm o n k e y s
resulted in oﬀspring demonstrating elevated cortisol levels
and altered responses to stress throughout life.
8. Mechanisms of Programmingfor ACS
A key aspect of the DOHaD hypothesis is that the eﬀects
of the environment are mediated by physiological and
metabolic eﬀects during fetal and early postnatal life [1–
5]. The HPA axis is a central mediator of the programming
process. Prenatal stress leads to numerous cardiovascular
and endocrine changes in the mother, including increases
in plasma ACTH, β-endorphin, cortisol, and catecholamine
concentrations. Although the placenta acts as a barrier to
many of these maternal factors, a number will still pass
to the fetus because of potential attenuation of 11-β-HSD-
2 in noncritical windows. There may be activation of the
fetal sympathetic nervous system which will contribute
to programming of the HPA axis and lead to an altered
physiological response in the fetus. Administration of ACS
can be seen as mimicking “prenatal stress.” Its eﬀects are
m o r ed i r e c ta si ti sa b l et ob y p a s st h ef u n c t i o n a lb a r r i e ro f
placental 11-β-HSD-2 and bind directly to the GR and MR
in the vulnerable regions of the hippocampus and alter HPA
axis activity. ACS has been shown from the clinical trials to
aﬀect in utero weight gain and lead to a reduced birth weight
[42], a surrogate crude measure which has been associated
with the development of hypertension, type 2 diabetes, and
cardiovascular disease in adulthood [81].
8.1. Role of Epigenetics. There is evidence that the early
environmentcanpermanentlyinﬂuencethegenomethrough
epigenetic mechanisms and in this way modiﬁes endocrine
function, metabolism, and behaviour of oﬀspring [82–87].
Gene expression can be epigenetically modiﬁed through
alterations in DNA methylation and chromatin structure
(i.e., histone acetylation). DNA methylation is a process
where a methyl group is covalently linked to cytosine [88].
Methylation patterns are established during early embryonic
development and maintained by DNA methyltransferases
[84]. In general, DNA methylation in regulatory regions
(e.g., promoters) reduces gene expression and represents
an important mechanism for tissue-speciﬁc gene silencing
[89]. In contrast, demethylation leads to gene activation
[88]. When methylation occurs in a gene promoter, the
methylgroupcaninterferewithtranscription factorbinding.
Alternatively, gene silencing may occur through targeting of
DNA-binding proteins. MeCP-1 and MeCP-2 (methyl cyto-
sine binding proteins 1 and 2) recognize methylated DNA
and recruit corepressors and histone modifying enzymes
such as histone deacetylases and histone methyltransferases
to methylated genes, precipitating an inactive chromatin
conﬁguration[88].Importanttothisproposal,keygenesthat
regulate HPA function (GR, CRH, POMC, and 11β-HSD-
2) have been shown to be epigenetically regulated [82, 89–
93]. Altered gene promoter methylation has been identiﬁed
in human diseases [90]. More recently, altered hippocampal
GR promoter methylation patterns has been demonstrated
in human suicide subjects [94]. Maternal stress/anxiety and
dietary protein restriction during pregnancy [92, 93, 95–98]
and altered levels of maternal care [82, 85, 99] can leave
permanent epigenetic marks in the genome and result in
stable life-long changes in gene expression in oﬀspring. Szyf
and Meaney have shown that increased maternal care in
rats leads to demethylation and increased histone acetylation
of the hippocampal GR promoter, which is maintained
throughout life [82]. Importantly, this eﬀect is gene-
promoter speciﬁc; other nonhippocampal GR promoters
are not aﬀected. Demethylation was speciﬁc to the NGFI-
A binding site in the GR promoter, resulting in increased
NGFI-A binding and increased GR expression. This leads
to increased glucocorticoid feedback and a decrease in HPA
activity [82]. The reduced promoter methylation could be
reversed in adulthood by central infusion of L-methionine
(a methyl donor) [86]. In other studies, protein restriction
during rat pregnancy has been shown to cause reduced
methylation of speciﬁc hepatic gene promoters, including
the GR, and a resultant increase in gene transcription in F1
oﬀspring. Again, this demethylation is gene-speciﬁc and can
be prevented by folate (a methyl donor) supplementation
during pregnancy [97]. Very recent rat and human studies
have shown that maternal stress/anxiety during pregnancy
leads to altered methylation of the hypothalamic CRH
promoter (rat oﬀspring) and GR promoter in umbilical
cord blood mononuclear cells (humans) [92, 93]. However,
of most importance, glucocorticoids have been shown to
cause permanent demethylation of speciﬁc fetal hepatic
g e n ep r o m o t e r si nl a t eg e s t a t i o n[ 100]. This demethylation
results in enhanced transcription factor binding, and this is
maintained following glucocorticoid withdrawal indicating
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modulate methylation status is through a reduction in folate
availability. In this regard, Cushing’s patients (with ele-
vated plasma cortisol) exhibit hyperhomocysteinemia [101].
Hyperhomocysteinemia inhibits the activity of DNA methyl-
transferases and induces hypomethylation [102]. There is
extremely strong evidence emerging indicating that fetal GC
exposure,beitendogenousorexogenousintheformofACS,
has profound inﬂuences on the fetal epigenome.
8.2. Transgenerational Eﬀects. Recent studies have begun
to show that the eﬀect of ACS exposure may not be
restricted to the immediate oﬀspring of the pregnancy at
risk but may aﬀect subsequent generations; this is known as
“transgenerational eﬀects”. These eﬀects have been observed
in the rat model where the oﬀspring of an F1 progeny
whose mothers were treated with dexamethasone in the ﬁnal
week of pregnancy were mated with males from the same
prenatal treatment. Both the F1 and F2 generation oﬀspring
exhibiteddecreasedweightatbirthcomparedtocontrolsand
also demonstrated abnormal endocrine responses to glucose
challenges [103]. The programming eﬀects were transmitted
by either maternal or paternal lines implying an epigenetic
mechanism. Further studies are needed to elucidate these
mechanisms and how this will translate into the clinical
realm.
9. The Need for Focused Research on
Long-Term Effects of ACS
Pregnant women at risk of preterm birth continue to
be a major clinical obstetrical issue. A single course of
ACS remains the standard of care in this clinical setting
to optimize fetal lung maturity. Because of concerns of
fetal growth alterations and potential neurodevelopmental
impairments, systematic repetitive administration of ACS
has not been adopted as standard care. However, because
of the short-term beneﬁts of reducing neonatal morbidity,
the more recent Cochrane Review supports the use of this
approach in identiﬁed high-risk women [42]. In addition,
the concept of “rescue” ACS has emerged in which ACS is
givenagainonlywhendeliveryhasagainbecomelikely[104].
Recentdatafromtworandomizedtrialsdemonstratebeneﬁts
in reducing acute neonatal pulmonary morbidity without
noticeable eﬀects on fetal growth [105, 106].
The long-term eﬀects of antenatal sGC exposure on HPA
axis activity and neurological function is well documented in
animal studies, and it appears that sGC, regardless of dose
exposure, is capable of aﬀecting fetal HPA axis development
causing permanent changes in the HPA axis that persists
through life and is manifested by chronic illness and
behavioral changes. The previous long-term studies of ACS
have focused only on major neurodevelopmental diﬃculties
(cerebral palsy, blindness, deafness, and cognition) to the
age of 2 years. However, the more recent animal studies
suggest that the long-term eﬀects of any exposure to sGC are
more related to behaviour and the cardiometabolic factors
contributing to chronic mental and physical illnesses, none
of which have been adequately assessed in the majority of
the long-term human follow-up studies. In retrospective
studies, there is some suggestion of the behaviour changes
seen with repeated exposure to sGC [46]. If early exposure
aﬀects hippocampal structure and alters function as the
myriad of studies in animal models suggest, then there is
likely to be an explosion of cognitive challenges, behavior
disorders, and, perhaps, the risk of psychological disorders
[107]. Similarly, if there is signiﬁcant alteration in the HPA
axis, then a generation of children and perhaps beyond are
prone to develop the chronic illnesses of adulthood, such as
heart disease, hypertension, type 2 diabetes.
The use of ACS, single or multiple courses, in the
obstetric management of women at risk for preterm birth
is likely not to diminish. Further studies are required on
how to optimize the use of ACS in those women who
remain undelivered 7 to 10 days after receiving an initial
course of ACS. In addition, it is critical to determine ACS
role, regardless of dosage, in “fetal programming” and its
potential impact on a generation of children as it relates
to behaviour, learning skills, and the potential for chronic
illness. If the impact can be identiﬁed, appropriate measures
can be implemented to minimize its eﬀect.
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